Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 20, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,400.62 pence per share.
Material Changes
On March 20, 2007, the Company purchased 500,000 of its Ordinary shares of 25 pence each. These shares are intended to be held in Treasury. Following this transaction, the total number of shares held in Treasury increased to 264,582,678.
Outlook and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future operations or risks. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Important Facts for Investors
- Treasury Share Count: The Company now holds 264,582,678 shares in Treasury.
- Shares in Issue: There are 5,745,104,759 shares in issue (excluding Treasury shares), representing total voting rights.
- Repurchase Details: 500,000 shares were bought on March 20, 2007, at 1,400.62 pence per share.
- Disclosure Rules: The share count in issue serves as the denominator for shareholders calculating notification requirements under the Financial Services Authority's Disclosure and Transparency Rules.